FDA Starts Review of Biogenís Therapy for Hemophilia B

by Kathy Jones on  March 5, 2013 at 9:06 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

The US Food and Drug Administration is currently reviewing Biogen Idec's application for a fusion protein therapy designed to treat hemophilia B, the company said.
 FDA Starts Review of Biogenís Therapy for Hemophilia B
FDA Starts Review of Biogenís Therapy for Hemophilia B

The company revealed that its drug, rFIXFc, has been designed to last longer than currently available drugs and allows patients to endure fewer treatments.

The FDA will be conducting a 10-month review of the drug and is expected to reach a decision in January next year.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Genetic Counseling Reiki and Pranic Healing von Willebrand Disease Bleeding Disorders Hemophilia Modified Atkins Diet: All You Need to Know 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive